Rezolute, Inc. RZLT
We take great care to ensure that the data presented and summarized in this overview for Rezolute, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RZLT
View all-
Federated Hermes, Inc. Pittsburgh, PA11.3MShares$53 Million0.13% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.86MShares$13.4 Million0.69% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.8MShares$13.1 Million2.6% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$11.9 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$10.9 Million0.0% of portfolio
-
Blackstone Inc New York, NY1.74MShares$8.2 Million0.04% of portfolio
-
Altium Capital Management LP New York, NY1.69MShares$7.96 Million2.69% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.58MShares$7.4 Million1.34% of portfolio
-
Ghost Tree Capital, LLC New York, NY1.47MShares$6.93 Million2.68% of portfolio
-
Adar1 Capital Management, LLC Austin, TX1.36MShares$6.39 Million1.33% of portfolio
Latest Institutional Activity in RZLT
Top Purchases
Top Sells
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Insider Transactions at RZLT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2025
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
10,549
+7.41%
|
$52,745
$5.04 P/Share
|
|
Feb 18
2025
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
10,000
+11.46%
|
$40,000
$4.7 P/Share
|
|
Feb 16
2025
|
Wladimir Hogenhuis |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+27.49%
|
-
|
|
Feb 16
2025
|
Gil M Labrucherie |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+50.0%
|
-
|
|
Feb 16
2025
|
Daron Evans CFO |
BUY
Grant, award, or other acquisition
|
Direct |
77,000
+25.25%
|
-
|
|
Feb 16
2025
|
Young Jin Kim |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+15.32%
|
-
|
|
Feb 16
2025
|
Nerissa Kreher |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+50.0%
|
-
|
|
Feb 16
2025
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
77,000
+36.96%
|
-
|
|
Feb 16
2025
|
Nevan C Elam CEO |
BUY
Grant, award, or other acquisition
|
Direct |
204,000
+49.06%
|
-
|
|
Feb 16
2025
|
Philippe Fauchet |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+50.0%
|
-
|
|
Dec 18
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
10,000
+6.22%
|
$40,000
$4.29 P/Share
|
|
Dec 12
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
9,000
+6.0%
|
$36,000
$4.6 P/Share
|
|
Sep 24
2024
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
4,259
+9.25%
|
$17,036
$4.7 P/Share
|
|
Jun 25
2024
|
Young Jin Kim |
BUY
Open market or private purchase
|
Indirect |
1,250,000
+14.81%
|
$5,000,000
$4.0 P/Share
|
|
Jun 25
2024
|
Wladimir Hogenhuis |
BUY
Open market or private purchase
|
Direct |
4,815
+11.38%
|
$19,260
$4.15 P/Share
|
|
Jun 14
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
3,300
+18.32%
|
$9,900
$3.94 P/Share
|
|
Jun 14
2024
|
Brian Kenneth Roberts Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
4,300
+3.72%
|
$12,900
$3.94 P/Share
|
|
Jun 14
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
40,000
+50.0%
|
$160,000
$4.04 P/Share
|
|
May 29
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Direct |
451
+0.37%
|
$1,353
$3.5 P/Share
|
|
May 24
2024
|
Daron Evans CFO |
BUY
Open market or private purchase
|
Indirect |
2,942
+18.45%
|
$8,826
$3.23 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 486K shares |
|---|---|
| Open market or private purchase | 1.48M shares |